
FTH Stock Forecast & Price Target
FTH Analyst Ratings
Bulls say
Faeth Therapeutics is an innovative biotechnology company with a promising drug candidate, PIKTOR, in development for endometrial and breast cancer. While the company has shown promising data and a strong cash balance, it also faces competition in the market from other drugs targeting the same pathways. However, PIKTOR's multi-way inhibition and potential advantages make it an attractive investment opportunity for those with a positive outlook on the company's potential success.
Bears say
Faeth Therapeutics is heavily reliant on the success of its PIKTOR program, which is still in the clinical stage and has not yet received approval from regulatory authorities. The company faces competition from well-established players in the industry and while serabelisib may have potential, its ultimate success is uncertain. The company's reliance on a single program and uncertainties in the competitive landscape pose significant financial risk and make the stock a risky investment with a negative outlook.
This aggregate rating is based on analysts' research of Sensei Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
FTH Analyst Forecast & Price Prediction
Start investing in FTH
Order type
Buy in
Order amount
Est. shares
0 shares